NovaBridge to Showcase Pipeline at Jefferies Healthcare Conference
Event summary
- NovaBridge Biosciences will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026.
- The presentation will include a company overview and one-on-one investor meetings.
- Key pipeline assets include givastomig for gastric cancer and VIS-101 for retinal diseases.
- Givastomig is in a global Phase 2 study following positive Phase 1b results.
- VIS-101 is set to begin a Phase 2b study in H2 2026.
The big picture
NovaBridge's participation in the Jefferies conference underscores its focus on accelerating access to innovative therapies. The company's pipeline, particularly givastomig and VIS-101, positions it in competitive segments of oncology and ophthalmology. Success in these areas could enhance its valuation and attractiveness to investors.
What we're watching
- Pipeline Momentum
- The pace at which givastomig advances through Phase 2 could validate NovaBridge's bispecific antibody strategy.
- Commercialization Timing
- Whether VIS-101's Phase 2b study yields compelling data to support further development in retinal diseases.
- Investor Sentiment
- How the market reacts to NovaBridge's strategic updates and pipeline progress during the conference.
Related topics